Cargando…
The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors
Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BBB) to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplas...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204086/ https://www.ncbi.nlm.nih.gov/pubmed/34141613 http://dx.doi.org/10.3389/fonc.2021.654921 |
_version_ | 1783708285042425856 |
---|---|
author | Cooper, Elizabeth Choi, Peter J. Denny, William A. Jose, Jiney Dragunow, Mike Park, Thomas I.-H. |
author_facet | Cooper, Elizabeth Choi, Peter J. Denny, William A. Jose, Jiney Dragunow, Mike Park, Thomas I.-H. |
author_sort | Cooper, Elizabeth |
collection | PubMed |
description | Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BBB) to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplasms, but despite their effectiveness in peripheral cancers, failed to show therapeutic success in brain tumors. This is largely due to their poor bioavailability and specificity towards brain tumors. A targeted delivery system might improve the efficacy of the candidate compounds by increasing the retention time in the tumor tissue, and minimizing the numerous side effects associated with the non-specific distribution of the chemotherapy agent. Heptamethine cyanine dyes (HMCDs) are a class of near-infrared fluorescence (NIRF) compounds that have recently emerged as promising agents for drug delivery. Initially explored for their use in imaging and monitoring neoplasms, their tumor-targeting properties have recently been investigated for their use as drug carrier systems. This review will explore the recent developments in the tumour-targeting properties of a specific group of NIRF cyanine dyes and the preclinical evidence for their potential as drug-delivery systems in the treatment of primary and metastatic brain tumors. |
format | Online Article Text |
id | pubmed-8204086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82040862021-06-16 The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors Cooper, Elizabeth Choi, Peter J. Denny, William A. Jose, Jiney Dragunow, Mike Park, Thomas I.-H. Front Oncol Oncology Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BBB) to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplasms, but despite their effectiveness in peripheral cancers, failed to show therapeutic success in brain tumors. This is largely due to their poor bioavailability and specificity towards brain tumors. A targeted delivery system might improve the efficacy of the candidate compounds by increasing the retention time in the tumor tissue, and minimizing the numerous side effects associated with the non-specific distribution of the chemotherapy agent. Heptamethine cyanine dyes (HMCDs) are a class of near-infrared fluorescence (NIRF) compounds that have recently emerged as promising agents for drug delivery. Initially explored for their use in imaging and monitoring neoplasms, their tumor-targeting properties have recently been investigated for their use as drug carrier systems. This review will explore the recent developments in the tumour-targeting properties of a specific group of NIRF cyanine dyes and the preclinical evidence for their potential as drug-delivery systems in the treatment of primary and metastatic brain tumors. Frontiers Media S.A. 2021-06-01 /pmc/articles/PMC8204086/ /pubmed/34141613 http://dx.doi.org/10.3389/fonc.2021.654921 Text en Copyright © 2021 Cooper, Choi, Denny, Jose, Dragunow and Park https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cooper, Elizabeth Choi, Peter J. Denny, William A. Jose, Jiney Dragunow, Mike Park, Thomas I.-H. The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors |
title | The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors |
title_full | The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors |
title_fullStr | The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors |
title_full_unstemmed | The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors |
title_short | The Use of Heptamethine Cyanine Dyes as Drug-Conjugate Systems in the Treatment of Primary and Metastatic Brain Tumors |
title_sort | use of heptamethine cyanine dyes as drug-conjugate systems in the treatment of primary and metastatic brain tumors |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204086/ https://www.ncbi.nlm.nih.gov/pubmed/34141613 http://dx.doi.org/10.3389/fonc.2021.654921 |
work_keys_str_mv | AT cooperelizabeth theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT choipeterj theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT dennywilliama theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT josejiney theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT dragunowmike theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT parkthomasih theuseofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT cooperelizabeth useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT choipeterj useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT dennywilliama useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT josejiney useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT dragunowmike useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors AT parkthomasih useofheptamethinecyaninedyesasdrugconjugatesystemsinthetreatmentofprimaryandmetastaticbraintumors |